LEXX (Lexaria Bioscience) Gross Margin

Official company branding of Lexaria Bioscience Corp. (LEXX)

Lexaria Bioscience is actively integrating its DehydraTECH system into the developments of major pharmaceutical holdings. Gross margin reflects this long-term trend, where the 49.00 mark serves as a key metric. Strong pricing power is driven by the uniqueness of the substance absorption process. Revenue is based on the licensing of intellectual property, which ensures software-like profitability in the absence of capital expenditures.

LEXX (Lexaria Bioscience) Gross Margin history from 07/04/2022 to 11/19/2026

Comprehensive metric breakdowns and analytics for Lexaria (LEXX)

Fundamental valuation:Lexaria Bioscience, LEXX
Manufactured product of Lexaria Bioscience Corp

Gross margin measures the efficiency of direct production by determining the profit share after deducting the cost of goods sold, allowing investors to identify asset overvaluation or the risk of declining returns through gross margin history. For Lexaria Bioscience (LEXX), this indicator is critical as it reflects the impact of licensing royalties and potential costs associated with intellectual property protection and the security of drug delivery technologies.

Direct competitors

Gross Profit Margin Haleon PLC (HLN)|Return on Gross Profit KVUE|Gross Profit Margin Verona Pharma Inc. VRNA|Gross Margin MENS|Ligand Pharmaceuticals - Gross Return on Sales|Gross Profitability Amneal AMRX|Gross Sales Margin Perrigo Company PLC|Alvotech Biopharmaceuticals - Gross Margin|Return on Sales by Gross Profit Liquidia Technologies LQDA|Galapagos N.V. (GLPG) - Gross Profitability|anipharmaceuticals.com - Gross Profit Rate|Return on Gross Profit MNKD|AMPH: Gross Profit Rate|Gross Profitability pacira.com (PCRX)|Gross Margin ARS Pharma (SPRY)|Theravance Biopharma - Return on Gross Profit|Gross Profit Ratio AQST (Aquestive Therapeutics)|SCPH: Return on Gross Profit|Gross Profit Margin Tectonic Therapeutic|TNXP: Gross Margin|SXT China (SXTC) - Gross Margin|Gross Profitability eupraxiapharma.com|BioHarvest Sciences (BHST) - Return on Sales by Gross Profit|Gross Profitability Invizyne (EXOZ)|ORMP - Gross Profit Margin|Gross Margin ENTX (Entera Bio)|Gross Sales Margin MindWalk Therapeutics|ABVC: Return on Gross Profit|CPIX - Gross Margin|QNTM (Quantum BioPharma) - Return on Gross Profit|Gross Profitability Margin FGEN (FibroGen)|TELO (Telomir Pharmaceuticals Corp) - Gross Margin|Gross Margin ranitherapeutics.com|Gross Profitability Synergy CHC Corp. (SNYR)|Rallybio Corp - Gross Return on Sales|Gross Margin PULM (pulmatrix.com)|Gross Profit Ratio PTHL (Pheton)|APM - Gross Profitability|Return on Sales by Gross Profit Lyra Therapeutics Inc LYRA|impactbiomedinc.com (IBO) - Gross Profitability|TNF Pharma (TNFA) - Gross Margin|YCBD (cbdmd.com) - Gross Margin|Return on Gross Profit PainReform (PRFX)|Gross Profitability Altamira Therapeutics (CYTO)|Return on Sales by Gross Profit Lipella Pharma|Optinose - Return on Gross Profit|Return on Sales by Gross Profit pieris.com (PIRS)|PROC - Gross Profitability|Gross Profitability Margin PTPI|QLI: Gross Margin|Gross Profit Margin ACELYRIN Inc. (SLRN)|TFFP (TFF Pharmaceuticals, Inc) - Gross Margin